--- title: "Assessing Galapagos (ENXTAM:GLPG) Valuation After Recent Share Price Weakness" type: "News" locale: "en" url: "https://longbridge.com/en/news/280872842.md" description: "Galapagos (ENXTAM:GLPG) has experienced a 4.0% decline in share price over the past day and a 12.7% drop over the past month, currently trading at €25.36. Despite this, the one-year total shareholder return is 7.9%. Analysts suggest a fair value of €30.34, indicating the stock may be undervalued. The company plans to redeploy €3 billion from cell therapy into mid to late-stage programs, aiming to enhance revenue. However, risks include restructuring costs and the execution of its business model transition. Investors are encouraged to assess the potential risks and rewards." datetime: "2026-03-28T09:45:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280872842.md) - [en](https://longbridge.com/en/news/280872842.md) - [zh-HK](https://longbridge.com/zh-HK/news/280872842.md) generator: "portal-rs" --- # Assessing Galapagos (ENXTAM:GLPG) Valuation After Recent Share Price Weakness ## Galapagos stock reaction and recent performance snapshot Galapagos (ENXTAM:GLPG) has drawn attention after a period of weaker share performance, with the stock showing a 4.0% decline over the past day and a 12.7% drop over the past month. See our latest analysis for Galapagos. At the current share price of €25.36, Galapagos has recently faced weaker momentum, with short term share price returns under pressure. However, the 1 year total shareholder return of 7.9% still sits ahead of longer term losses. If you are comparing Galapagos with other healthcare names, it could be a useful time to see what is moving in 124 healthcare AI stocks With Galapagos trading at €25.36 and metrics like an intrinsic discount of 12.5% and an 18.9% gap to the €30.15 analyst target, the key question is whether this indicates potential value or whether markets already reflect expectations for future growth. ## Most Popular Narrative: 16.4% Undervalued Against the last close of €25.36, the most followed narrative places Galapagos’ fair value at about €30.34, framing the current gap as valuation upside that hinges on how its business model transition plays out. > *Redeployment of approximately EUR 3 billion of cash from capital intensive cell therapy into externally sourced, mid to late stage programs should convert balance sheet strength into accretive revenue and earnings streams over time.* *Read the complete narrative.* Curious what turns a cash rich balance sheet and shrinking revenue base into that fair value. The narrative leans heavily on margin rebuild, repositioned earnings power and a future profit multiple that needs those assumptions to stick. **Result: Fair Value of €30.34 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, risks around executing the shift into externally sourced assets and managing up to €200 million of restructuring cash costs could easily challenge this undervaluation story. Find out about the key risks to this Galapagos narrative. ## Next Steps With mixed views on risk and reward running through this story, it makes sense to look at the numbers yourself and move quickly to your own take using 2 key rewards and 2 important warning signs. ## Looking for more investment ideas? If Galapagos has caught your attention, do not stop here. Broaden your watchlist now so you can spot opportunities before the crowd moves. - Target resilient income by scanning companies that offer reliable payouts and higher yields through the 470 dividend fortresses. - Zero in on quality at a discount by checking out the 238 high quality undervalued stocks that combine fundamentals with potential upside. - Secure peace of mind by filtering for companies with stronger finances using the solid balance sheet and fundamentals stocks screener (381 results). *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [GLPG.US](https://longbridge.com/en/quote/GLPG.US.md) - [LKFT.US](https://longbridge.com/en/quote/LKFT.US.md) ## Related News & Research - [Bank of America tops 10% stake in Lakefront Biotherapeutics voting rights disclosure](https://longbridge.com/en/news/296823581.md) - [02:10 ETKeymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt](https://longbridge.com/en/news/296866579.md) - [05:13 ETKeymed Biosciences Announces 2026 H1 Results and Business Updates](https://longbridge.com/en/news/296594656.md) - [Lakefront Biotherapeutics Buys Back 97,497 Shares Under Ongoing Repurchase Program](https://longbridge.com/en/news/294869610.md) - [Lakefront Biotherapeutics Buys Back Over 104,000 Shares Under June 2026 Repurchase Program](https://longbridge.com/en/news/291976749.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**